| 1. |
Antibacterials remain controversial in acute pancreatitis |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1435,
2004,
Page 2-2
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2004
数据来源: ADIS
|
| 2. |
FLT-3 inhibitors: promising targeted therapy for paediatric cancer |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1435,
2004,
Page 3-3
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2004
数据来源: ADIS
|
| 3. |
Artesunate/amodiaquine will replace chloroquine as the first-line treatment for malaria in Ghana |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1435,
2004,
Page 4-4
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2004
数据来源: ADIS
|
| 4. |
Antiulcer coprescribing threatens COX-2 inhibitor cost savings |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1435,
2004,
Page 5-5
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2004
数据来源: ADIS
|
| 5. |
Ranolazine promising in chronic angina pectoris |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1435,
2004,
Page 6-6
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2004
数据来源: ADIS
|
| 6. |
Intranasal ciclesonide nothing to sneeze at in allergic rhinitis |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1435,
2004,
Page 7-7
RM Poole,
Preview
|
|
摘要:
An intranasal formulation of the corticosteroid ciclesonide has dose-dependent efficacy in patients with seasonal allergic rhinitis, according to a study presented at the 60th Annual Meeting of the American Association of Allergy, Asthma and Immunology (AAAAI) [San Francisco, US; March 2004]. Daily doses of intranasal ciclesonide 100 µg/day or 200 µg/day produced significant improvements in nasal symptoms, and had a tolerability profile similar to that of placebo, with the 200 µg/day dosage providing the greatest benefit.
ISSN:1173-8324
出版商:ADIS
年代:2004
数据来源: ADIS
|
| 7. |
Salcaprozate sodium enables GI absorption of oral insulin |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1435,
2004,
Page 8-8
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2004
数据来源: ADIS
|
| 8. |
Virosome-adjuvanted flu vaccine safe and highly immunogenic |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1435,
2004,
Page 9-9
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2004
数据来源: ADIS
|
| 9. |
Tegafur/uracil: beneficial adjuvant for stage I lung adenocarcinoma |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1435,
2004,
Page 10-10
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2004
数据来源: ADIS
|
| 10. |
Budesonide/formoterol single inhaler therapy superior in asthma |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1435,
2004,
Page 11-12
RM Poole,
Preview
|
|
摘要:
Single inhaler therapy with budesonide/formoterol [Symbicort SiT] provides greater asthma control than a higher dosage of budesonide plus terbutaline rescue, according to results from two phase III studies presented at the 60th Annual Meeting of the American Academy of Allergy, Asthma and Immunology (AAAAI) [San Francisco, US; March 2004]. In the first study, morning peak expiratory flow (PEF) was significantly increased in budesonide/formoterol recipients, compared with patients given budesonide plus terbutaline. Furthermore, a significant 70% reduction in the risk of severe exacerbations was achieved among budesonide/formoterol, compared with budesonide plus terbutaline, recipients. In the second study, patients with moderate-to-severe asthma had a 39% lower risk of severe exacerbations when receiving budesonide/formoterol than when treated with budesonide plus terbutaline.
ISSN:1173-8324
出版商:ADIS
年代:2004
数据来源: ADIS
|
首页
